- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.81 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
- 2 x UFP: 5-FLUORO-2'-DEOXYURIDINE-5'-MONOPHOSPHATE(Non-covalent)
UFP.2: 15 residues within 4Å:- Chain A: R.257, Y.342, C.402, H.403, Q.422, R.423, S.424, C.425, D.426, N.434, H.464, Y.466
- Chain B: R.382, R.383
- Ligands: OEA.3
12 PLIP interactions:10 interactions with chain A, 2 interactions with chain B- Hydrophobic interactions: A:D.426
- Hydrogen bonds: A:Q.422, A:S.424, A:S.424, A:D.426, A:N.434, A:N.434, A:H.464
- Salt bridges: A:R.257, A:R.423, B:R.382, B:R.383
UFP.6: 18 residues within 4Å:- Chain A: R.382, R.383
- Chain B: R.257, W.316, Y.342, L.399, C.402, H.403, Q.422, R.423, S.424, C.425, D.426, G.430, N.434, H.464, Y.466
- Ligands: OEA.7
12 PLIP interactions:10 interactions with chain B, 2 interactions with chain A- Hydrophobic interactions: B:D.426
- Hydrogen bonds: B:Q.422, B:S.424, B:D.426, B:N.434, B:N.434, B:H.464, B:Y.466
- Salt bridges: B:R.257, B:R.423, A:R.382, A:R.383
- 2 x OEA: 2-({4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]benzene-1-carbonyl}amino)-4-methoxybenzoic acid(Non-covalent)
OEA.3: 17 residues within 4Å:- Chain A: K.284, A.287, I.315, W.316, N.319, L.399, D.426, G.428, L.429, G.430, F.433, Y.466, I.515, M.517, M.519, A.520
- Ligands: UFP.2
11 PLIP interactions:11 interactions with chain A- Hydrophobic interactions: A:I.315, A:I.315, A:L.429, A:F.433, A:F.433
- Hydrogen bonds: A:R.257, A:N.319, A:A.520
- Water bridges: A:N.319
- Salt bridges: A:D.426
- pi-Stacking: A:W.316
OEA.7: 18 residues within 4Å:- Chain B: K.284, A.287, S.290, I.315, W.316, N.319, L.399, D.426, G.428, L.429, G.430, F.433, Y.466, I.515, M.517, M.519, A.520
- Ligands: UFP.6
12 PLIP interactions:12 interactions with chain B- Hydrophobic interactions: B:A.287, B:I.315, B:I.315, B:L.429, B:F.433, B:F.433
- Hydrogen bonds: B:S.290, B:N.319, B:Y.466, B:A.520
- Salt bridges: B:D.426
- pi-Stacking: B:W.316
- 2 x MTX: METHOTREXATE(Non-covalent)
MTX.4: 17 residues within 4Å:- Chain A: V.9, V.10, A.11, L.25, D.32, L.33, K.34, F.36, S.37, T.58, I.62, L.67, R.70, C.113, Y.119, T.134
- Ligands: NDP.1
10 PLIP interactions:10 interactions with chain A- Hydrophobic interactions: A:L.33, A:I.62
- Hydrogen bonds: A:V.10, A:C.113
- Water bridges: A:V.10, A:T.134
- Salt bridges: A:D.32, A:K.34, A:R.70
- pi-Stacking: A:F.36
MTX.8: 17 residues within 4Å:- Chain B: V.9, V.10, A.11, L.25, D.32, L.33, K.34, F.36, S.37, T.58, I.62, L.67, R.70, C.113, Y.119, T.134
- Ligands: NDP.5
9 PLIP interactions:9 interactions with chain B- Hydrophobic interactions: B:L.33, B:I.62
- Hydrogen bonds: B:V.9, B:V.10, B:T.134
- Salt bridges: B:D.32, B:K.34, B:R.70
- pi-Stacking: B:F.36
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Czyzyk, D.J. et al., Structure activity relationship towards design of cryptosporidium specific thymidylate synthase inhibitors. Eur.J.Med.Chem. (2019)
- Release Date
- 2019-10-02
- Peptides
- Bifunctional dihydrofolate reductase-thymidylate synthase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.81 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
- 2 x UFP: 5-FLUORO-2'-DEOXYURIDINE-5'-MONOPHOSPHATE(Non-covalent)
- 2 x OEA: 2-({4-[(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)methyl]benzene-1-carbonyl}amino)-4-methoxybenzoic acid(Non-covalent)
- 2 x MTX: METHOTREXATE(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Czyzyk, D.J. et al., Structure activity relationship towards design of cryptosporidium specific thymidylate synthase inhibitors. Eur.J.Med.Chem. (2019)
- Release Date
- 2019-10-02
- Peptides
- Bifunctional dihydrofolate reductase-thymidylate synthase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B